CN111093671A - 以托吡坦对特应性皮炎的改进治疗 - Google Patents

以托吡坦对特应性皮炎的改进治疗 Download PDF

Info

Publication number
CN111093671A
CN111093671A CN201880059276.3A CN201880059276A CN111093671A CN 111093671 A CN111093671 A CN 111093671A CN 201880059276 A CN201880059276 A CN 201880059276A CN 111093671 A CN111093671 A CN 111093671A
Authority
CN
China
Prior art keywords
patient
toppitant
dose
genotype
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880059276.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·波利梅洛伯罗斯
肖长福
G·比尔茨尼克斯
A·海特曼
S·斯迈斯泽克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CN111093671A publication Critical patent/CN111093671A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Physical Education & Sports Medicine (AREA)
CN201880059276.3A 2017-09-13 2018-08-30 以托吡坦对特应性皮炎的改进治疗 Pending CN111093671A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762558303P 2017-09-13 2017-09-13
US62/558,303 2017-09-13
US201762572456P 2017-10-14 2017-10-14
US62/572,456 2017-10-14
PCT/US2018/048825 WO2019055225A1 (en) 2017-09-13 2018-08-30 ENHANCED TREATMENT OF ATOPIC DERMATITIS USING TRADIPITANT

Publications (1)

Publication Number Publication Date
CN111093671A true CN111093671A (zh) 2020-05-01

Family

ID=63684468

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880059276.3A Pending CN111093671A (zh) 2017-09-13 2018-08-30 以托吡坦对特应性皮炎的改进治疗

Country Status (11)

Country Link
US (1) US11549147B2 (https=)
EP (2) EP4487912A3 (https=)
JP (1) JP7347743B2 (https=)
KR (2) KR20200054232A (https=)
CN (1) CN111093671A (https=)
AU (1) AU2018331267B2 (https=)
CA (1) CA3073998A1 (https=)
CL (1) CL2020000655A1 (https=)
IL (1) IL272949B2 (https=)
MX (2) MX2020002852A (https=)
WO (1) WO2019055225A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978736C (en) 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
CN112218636B (zh) 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
JP2023515167A (ja) * 2020-02-25 2023-04-12 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
PL3996169T3 (pl) 2020-05-07 2025-05-12 Lg Energy Solution, Ltd. Wysokoniklowy arkusz elektrody i sposób jego wytwarzania
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
CN120641099A (zh) 2022-12-21 2025-09-12 万达制药公司 使用曲地匹坦的治疗方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263498B (https=) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
KR100755577B1 (ko) 2002-04-26 2007-09-12 일라이 릴리 앤드 캄파니 타키키닌 수용체 길항제로서의 트리아졸 유도체
BR0309486A (pt) 2002-04-26 2005-02-09 Lilly Co Eli Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
NZ580480A (en) 2003-10-24 2010-02-26 Lilly Co Eli Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
WO2007096782A2 (en) 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compositions for disorders associated wtth metachromatic cell activation
CN101568523A (zh) 2006-12-20 2009-10-28 伊莱利利公司 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]－吡啶－3－基｝·(2－氯苯基)甲酮的新中间体和方法
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
BR112015031724A2 (pt) 2013-06-24 2017-07-25 Tigercat Pharma Inc uso do antagonista do receptor nk-1 serlopitant em pruridos
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VANDA PHARMACEUTICALS: "NCT02651714", 《CLINICALTRIALS.GOV》 *

Also Published As

Publication number Publication date
AU2018331267A1 (en) 2020-04-16
EP4487912A3 (en) 2025-03-26
MX2024004377A (es) 2024-04-26
WO2019055225A1 (en) 2019-03-21
MX2020002852A (es) 2020-07-22
EP3681505C0 (en) 2024-12-18
AU2018331267B2 (en) 2024-03-07
EP3681505B1 (en) 2024-12-18
CA3073998A1 (en) 2019-03-21
CL2020000655A1 (es) 2020-10-09
IL272949B2 (en) 2025-07-01
IL272949B1 (en) 2025-03-01
IL272949A (en) 2020-04-30
JP7347743B2 (ja) 2023-09-20
JP2020533381A (ja) 2020-11-19
EP4487912A2 (en) 2025-01-08
US20210062262A1 (en) 2021-03-04
RU2020112222A (ru) 2021-10-13
US11549147B2 (en) 2023-01-10
KR20200054232A (ko) 2020-05-19
BR112020004964A2 (pt) 2020-09-15
EP3681505A1 (en) 2020-07-22
KR20250036264A (ko) 2025-03-13

Similar Documents

Publication Publication Date Title
CN111093671A (zh) 以托吡坦对特应性皮炎的改进治疗
Yoshida et al. Skin barrier defects in atopic dermatitis: from old idea to new opportunity
JP6891385B2 (ja) トラジピタントによる治療方法
Cogo et al. Increased serum QUIN/KYNA is a reliable biomarker of post-stroke cognitive decline
EP4005570B1 (en) Pridopidine for use in treating rett syndrome
Schlagal et al. Maternal opioid exposure culminates in perturbed murine neurodevelopment and hyperactive phenotype in adolescence
Muñoz et al. Glycomacropeptide attenuates inflammation, pruritus, and Th2 response associated with atopic dermatitis induced by 2, 4‐dinitrochlorobenzene in rat
Landsberg et al. Effects of clomipramine on cats presented for urine marking
JP2017529321A (ja) 炎症性腸疾患を診断ならびに処置するための方法および組成物
Morales-Mulia Intra-accumbal orexin-1 receptor inhibition prevents the anxiolytic-like effect of ethanol and leads to increases in orexin-A content and receptor expression
Xu et al. BML-111 inhibit H2O2-induced pyroptosis and osteogenic dysfunction of human periodontal ligament fibroblasts by activating the Nrf2/HO-1 pathway
CN119318706A (zh) Nr3a作为蛋白靶点在筛选或制备预防和/或治疗抑郁样行为的药物中的应用
US20230073637A1 (en) Treatment of atopic dermatitis with tradipitant
Sala-Cunill et al. The role of mast cells mediators in angioedema without wheals
RU2812890C2 (ru) Усовершенствованное лечение атопического дерматита традипитантом
RU2793237C2 (ru) Усовершенствованное лечение атопического дерматита традипитантом
Larsson et al. Effects of 5-lipoxygenase inhibitor zileuton on airway responses to inhaled swine house dust in healthy subjects
BR112020004964B1 (pt) Método para determinar uma dose eficaz de tradipitant ou um sal farmaceuticamente aceitável do mesmo
CA3169449A1 (en) Improved treatment of atopic dermatitis with tradipitant
Mahmoud et al. Trimetazidine Attenuates Ulcerative Colitis-Linked Extrapyramidal Dysfunction by Mediated Dectin-1/LRRK2/α-Synuclein Autophagy Axis
Spears et al. Factors influencing individual variability in the therapeutic response to corticosteroids in asthma
Fonseca et al. 6ER-014 Analysis of the evolution of interleukin-6 in COVID-19 patients after being treated with dexamethasone
Wang et al. The effects of Kai-Xin-San in alleviating chronic social defeat stress-induced depression-like behaviors are associated with CD4+ T cells.
Samaka et al. Nucleocytoplasmic expression of autophagy-related protein 7 in psoriasis.
Xu et al. BML-111 inhibit H

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination